Not Signed In -
Risedronate |
Actonel; risedronate sodium |
Risedronate Systematic (IUPAC) name (1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid Identifiers CAS number 105462-24-6 ATC code M05BA07 PubChem 5245 DrugBank APRD00410 Chemical data Formula C7H11NO7P2 Mol. weight 283.112 g/mol Pharmacokinetic data Bioavailability 0.63% Protein binding ~24% Metabolism None Half life 1.5 hours Excretion Renal and fecal Therapeutic considerations Pregnancy cat. B3(AU) C(US) Legal status POM(UK) â ...
Wikipedia - [full article]
Risedronate Clinical Trials
- Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
ClinicalTrials.gov Identifier: NCT00106028 - Active, not recruiting
Osteogenesis Imperfecta
- Risedronate Sodium on Bone in Postmenopausal Women with Hormone-Receptor-Positive Early Breast Cancer
ClinicalTrials.gov Identifier: NCT00082277 - Active, not recruiting
Breast Cancer
- Risedronate for the Treatment of Osteoporosis for People with Spinal Cord Injury.
ClinicalTrials.gov Identifier: NCT00138866 - Active, not recruiting
Spinal Cord Injury; Osteoporosis
- Risedronate in Osteopenic Postmenopausal Women
ClinicalTrials.gov Identifier: NCT00345644 - Active, not recruiting
Osteoporosis
- Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
ClinicalTrials.gov Identifier: NCT00054418 - Active, not recruiting
Osteoporosis; stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer
- Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients with Prostate Cancer
ClinicalTrials.gov Identifier: NCT00043069 - Active, not recruiting
Osteoporosis; stage I prostate cancer; stage II prostate cancer; stage III prostate cancer
- A Study of Monthly Risedronate for Osteoporosis
ClinicalTrials.gov Identifier: NCT00247273 - Active, not recruiting
Postmenopausal Osteoporosis
- The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women with Breast Cancer Following Chemotherapy (REBBeCA Study)
ClinicalTrials.gov Identifier: NCT00118508 - Active, not recruiting
Osteoporosis
- Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
ClinicalTrials.gov Identifier: NCT00266708 - Active, not recruiting
Renal Transplant Osteodystrophy
- Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
ClinicalTrials.gov Identifier: NCT00386360 - Recruiting
Osteopenia
- Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
ClinicalTrials.gov Identifier: NCT00216060 - Active, not recruiting
Metastatic Prostate Cancer
- A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
ClinicalTrials.gov Identifier: NCT00377234 - Active, not recruiting
Post-Menopausal Osteoporosis
- OPTAMISE: Open-Label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide
ClinicalTrials.gov Identifier: NCT00130403 - Completed
Osteoporosis, Postmenopausal
- SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.
ClinicalTrials.gov Identifier: NCT00460733 - Recruiting
Colles' Fracture
- A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
ClinicalTrials.gov Identifier: NCT00541658 - Recruiting
Postmenopausal Osteoporosis
- Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
ClinicalTrials.gov Identifier: NCT00221299 - Recruiting
Glucocorticoid Induced Osteoporosis
- Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
ClinicalTrials.gov Identifier: NCT00136058 - Active, not recruiting
Osteoporosis; Hip Fracture
- Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
ClinicalTrials.gov Identifier: NCT00405392 - Recruiting
Postmenopausal Osteoporosis
- Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
ClinicalTrials.gov Identifier: NCT00324714 - Recruiting
Breast Cancer; Osteoporosis
- Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
ClinicalTrials.gov Identifier: NCT00426777 - Recruiting
Prostate Cancer
- Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
ClinicalTrials.gov Identifier: NCT00343252 - Recruiting
Postmenopausal Osteoporosis; Back Pain; Spinal Fracture
- Bone Loss in Women with Anorexia Nervosa
ClinicalTrials.gov Identifier: NCT00089843 - Recruiting
Anorexia Nervosa
- Treatment of Paget's Disease using Risedronate as a Comparator
ClinicalTrials.gov Identifier: NCT00050258 - Recruiting
Paget's Disease of Bone
- Risedronate for the Prevention of Osteoporosis in People with Spinal Cord Injury.
ClinicalTrials.gov Identifier: NCT00150696 - Completed
Acute spinal cord injury.
- Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
ClinicalTrials.gov Identifier: NCT00445575 - Recruiting
Fibrous Dysplasia of Bone
- Satisfaction and Compliance of Risedronate in PMO
ClinicalTrials.gov Identifier: NCT00549965 - Completed
Osteoporosis, Postmenopausal
- Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
ClinicalTrials.gov Identifier: NCT00577720 - Completed
Postmenopausal Women
- The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
ClinicalTrials.gov Identifier: NCT00372372 - Completed
Osteoporosis
- Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
ClinicalTrials.gov Identifier: NCT00577421 - Completed
Postmenopausal Osteoporosis
- Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered Monthly in Women With Low Bone Mineral Density
ClinicalTrials.gov Identifier: NCT00577837 - Completed
Postmenopausal
- Risedronate in Postmenopausal Women With Low Bone Density
ClinicalTrials.gov Identifier: NCT00351091 - Completed
Osteoporosis, Postmenopausal
- Risedronate Sodium in Post Menopausal Osteoporosis
ClinicalTrials.gov Identifier: NCT00453492 - Completed
Osteoporosis, Postmenopausal
- Pharmacokinetics of a Single 14C-Labeled Dose of Risedronate or Alendronate Followed by Once-a-Week Unlabeled Oral Dose
ClinicalTrials.gov Identifier: NCT00577850 - Completed
Osteopenia; Osteoporosis
- Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
ClinicalTrials.gov Identifier: NCT00358176 - Completed
Osteoporosis Postmenopausal
- Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
ClinicalTrials.gov Identifier: NCT00353080 - Completed
Osteoporosis, Postmenopausal
- Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
ClinicalTrials.gov Identifier: NCT00402441 - Completed
Osteoporosis, Postmenopausal
Resources
- Actonel (Drug Digest)
- Actonel Consumer Information (U.S. Food and Drug Administration)
email this page
print this page
bookmark this page
feedback on this page
